The COVID-19 testing landscape is continually changing as additional tests receive an emergency use authorization from the FDA. Technology to conduct molecular, antigen, and serology tests is now available and additional technologies are anticipated. The availability of evidence regarding the performance of these different tests as well as guidelines for their best use in different populations is still limited.
Testing resource constraints continue, especially related to swabs, reagents, and media. In addition, many commercial laboratories are experiencing high volumes and test results are delayed. For these reasons, it is important to continue to use an evidence-based approach when making COVID-19 testing priorities.

свернуть